Medical innovation from previous failure
Going from university research to an industrial start-up was “a bit of craziness, because I didn’t know anything about medical diagnostics,” says João. But he did know where to find the right guidance: previous failure.
“A few years earlier I had tried my first start-up. It was not a success but I learnt a lot of things. First, that I could not do it all on my own. I had to find the best people, biochemists, physicians, to help me make this possible. Second, that identifying a large unmet need and developing a technology that works is not enough. If you want to move from demonstrating to producing, you need money.”
So in mid-2014 João applied for a loan from the European Investment Bank. “I filled an online form available on the EIB website without too much hope. We are small and, though we have amazing technology and people, ours is a risky business. But along the process I was really surprised by the way people from the Bank were involved, and by the fact that such a big institution made the step of believing in an adventure such as Biosufit.”
A Biosurfit researcher checks the functioning of the machines at the company’s lab. Located at the Universidade Nova de Lisboa, the facilities are becoming too small for the growing team. The EIB loan will help finance a new factory
With a EUR 12 million loan from the EU bank, João and team are building a new factory in Lisbon, hiring new people and investing to deliver new test options to doctors. The loan is supported by InnovFin – EU Finance for Innovators, an investment programme designed to facilitate access to finance for innovative businesses.
Medical innovation gets innovative financing
The EIB’s loan to Biosurfit is actually a new product called quasi-equity. The product aims to fill the market gap that afflicts many R&D-intensive, small and medium-sized European companies. At an early stage of development, it’s a challenge for such companies to find debt financing from the private sector. Their financing needs are also smaller than a regular EIB loan. Here’s how it works:
The EIB makes a loan to an innovative company like Biosurfit. Steady repayment of the loan or interest payments would drain the company’s coffers just when it needs to be investing in research and development. Quasi-equity loans allow more flexible repayment that can be based on the performance of the company.
“Without the backing from the EIB we would go slower and we’d be unable to deliver to the market the products they are asking for. This loan allows us to develop and attempt to conquer the world in a quicker way,” João says with a smile.
A blood test at the company’s lab
Biosurfit’s technology analyses a small drop of blood placed inside a disposable CD with a special CD drive, also developed by the team
Biosufit is now selling its technology to hospitals and doctors’ offices in the Netherlands, Belgium, Norway, Switzerland and the Middle East. They expect to expand to the US and Asia in a couple of years.
João has travelled the world over explaining how Biosurfit’s Portuguese innovation helps both patients and doctors. “Coming from a country that’s not well known for its science, we have an additional responsibility to show we are capable of doing cutting edge technology. People are surprised at first, but showing the technology working always makes the difference!”